Quince Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Quince Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
  • Quince Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$5.49M, a 2.64% decline year-over-year.
  • Quince Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$53.3M, a 90.1% decline year-over-year.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$31.4M, a 39.2% increase from 2022.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$51.7M, a 42.6% increase from 2021.
  • Quince Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$89.9M, a 17% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$53.3M -$5.49M -$141K -2.64% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$53.1M -$27.7M -$22.8M -468% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$30.3M -$11.1M +$1.11M +9.02% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$31.4M -$8.89M -$3.36M -60.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$28M -$5.35M +$2.57M +32.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$30.6M -$4.89M +$11.7M +70.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$42.3M -$12.3M +$9.39M +43.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$51.7M -$5.53M +$17.9M +76.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$69.5M -$7.92M +$13.8M +63.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$83.3M -$16.6M +$5.19M +23.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$88.5M -$21.6M +$1.45M +6.26% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$89.9M -$23.4M -$2.84M -13.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$87.1M -$21.7M -$200K -0.93% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$86.9M -$21.8M -$4.14M -23.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$82.8M -$23.1M -$5.91M -34.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$76.8M -$20.6M -$8.18M -66% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 -$68.7M -$21.5M -$11.6M -118% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 -$57M -$17.6M -$8.55M -94.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$48.5M -$17.2M -$11.5M -202% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$37M -$12.4M -$8.91M -257% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$28.1M -$9.86M -$7.34M -291% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$20.7M -$9.06M -$5.95M -192% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$14.8M -$5.68M -$2.3M -68.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 -$12.5M -$3.47M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-01
Q3 2018 -$2.52M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$3.11M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 -$3.38M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.